fluciclatide

Fluciclatide is an investigational radiopharmaceutical, specifically a small synthetic cyclic peptide containing an RGD (Arg-Gly-Asp) motif, labeled with the positron-emitting isotope fluorine F 18. It is designed for use as a PET imaging agent to detect and quantify tumor cells and angiogenesis in vivo. The RGD sequence enables selective binding to integrin receptors αvβ3 and αvβ5, which are highly expressed on tumor cells and the endothelial cells of tumor vasculature. This mechanism allows fluciclatide to visualize tumors such as high-grade glioma, lung cancer, kidney neoplasms, melanoma, and renal cell carcinoma by targeting these integrins involved in angiogenesis and metastasis. Fluciclatide has been investigated primarily as a biomarker for monitoring therapeutic response to antiangiogenic treatments[1][2][3][4][5][6].

Other names

fluciclatide F 18FLUCICLATIDE (18F)Fluciclatide (f-18)879894-00-5879894-01-6